The bill seeks to amend Section 60A-2-204 of the Code of West Virginia by adding crystalline polymorph psilocybin to the list of Schedule I drugs, reflecting its recent approval by the FDA and DEA. This inclusion acknowledges the therapeutic potential of psilocybin and aligns state law with federal regulations. The bill retains the existing framework for categorizing Schedule I substances, which includes a variety of opiates, hallucinogens, and synthetic cannabinoids, without proposing any deletions from current law.

Furthermore, the legislation aims to regulate various synthetic substances, including cannabinoids, tryptamines, depressants, and stimulants, by specifying controlled compounds and their derivatives. It also introduces a provision for the legal prescription, distribution, and marketing of an organic psilocybin substance known as COMP360, contingent upon FDA approval and DEA scheduling. This move indicates a progressive shift in drug policy, recognizing the potential therapeutic applications of certain psychedelic substances while ensuring comprehensive regulation of synthetic drugs.

Statutes affected:
Introduced Version: 60A-2-204
Committee Substitute: 60A-2-204
Engrossed Committee Substitute: 60A-2-204